Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Sansom S, Lasry A, Hicks KA. The optimal allocation of HIV prevention dollars. Presented at the Centers for Disease Control and Prevention Division of HIV/AIDS Prevention Project Officers' Meeting; December 2006.
Hicks KA. A model for the efficient allocation of hiv prevention resources. Poster presented at the Centers for Disease Control and Prevention Division of HIV/AIDS Prevention Project Officers' Meeting; December 2006.
Hicks KA. Making use of cost-effectiveness analysis in the community planning process: methods and tools. Presented at the Centers for Disease Control and Prevention Division of HIV/AIDS Prevention Project Officers' Meeting; December 2006.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.
Mauskopf JA, Brogan AJ, Smets E, Martin S. Cost-effectiveness of darunavir (TMC114)/ritonavir compared with currently available protease inhibitors in treatment-experienced HIV patients. Poster presented at the 8th International Congress on Drug Therapy in HIV Infection; November 2006.
Javitt JC, Wolowacz SE, Roskell NS, Maciver F, Kelly S, Pleil AM, Zlateva GP. Cost-effectiveness of pegaptanib in age-related macular degeneration: the impact of differences between USA and UK health care systems. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Wolowacz SE, Roskell NS, Maciver F, Kelly S. Cost-utility analysis for pegaptanib in age-related macular degeneration in the UK: the impact of demographic and disease characteristics. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.
Earnshaw SR, Graham CN, Amonkar MM, Poston SA, Barr CE. Cost-effectiveness of ibandronate intravenous injection in the treatment of US women with postmenopausal osteoporosis. Poster presented at the 2006 American College of Rheumatology Scientific Meeting; November 2006.
Earnshaw SR, Pignone M, Tice J, Pletcher M. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Poster presented at the Annual Meeting of the Institute for Operations Research and the Management Sciences; November 2006.
Cowell W, Amonkar M, Cooper A, Earnshaw SR, Beard SM, Lynch N, Middelhoven H. Ibandronate vs. alendrolate: a cost-effectiveness analysis using persist results. Poster presented at the 2006 American College of Rheumatology Scientific Meeting; November 2006.
Wolowacz SE. The National Institute for Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: an update on the first round of submissions. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006.
Candrilli SD, Davis KL, Joshi AV, Tortella BJ. Healthcare utilization and costs associated with blunt and penetrating trauma in a United States managed care population. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006.
Sculpher M, Longson C, Wolowacz SE, Khan S. The new National Institute of Health And Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first round of completed appraisals. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 28, 2006. Copenhagen, Denmark.
Shearer A, Gazzard B, Graham CN, Davis EA, Mauskopf J, Kitahata M, Saag MS, Earnshaw SR. Simulation modeling of adherence and resistance on long-term outcomes in HIV. Poster presented at the Infectious Disease Society of America 44th Annual Meeting; October 15, 2006.
Graham CN, Earnshaw SR, Smith DG, Hogue S, Gitchell J, Marsh H, Becker W, Saunders M. Assessing the impact of smoking cessation therapies on a managed care organization's budget. Poster presented at the Academy of Managed Care Pharmacy Educational Conference; October 7, 2006.
Davis KL, Joshi AV, Tortella BJ, Candrilli SD. The direct economic burden of blunt and penetrating trauma in a managed care population. Poster presented at the American Association for the Surgery of Trauma Annual Meeting; September 30, 2006. New Orleans, LA.
Earnshaw SR, Beard SM, Lynch NO, Cooper A, Cowell W, Middelhoven H. A comparison of the cost-effectiveness of bisphosphonates using persistence data from a UK propsective rct. Poster presented at the 28th Annual Meeting of the American Society for Bone and Mineral Research; September 19, 2006.
Davis KL, Allen JK, Kirsch J, Davis KH, Edin HM. The prevalence of treatment non-adherence among patients with parkinson's disease in a United States managed care population. Poster presented at the 10th Congress of the European Federation of Neurological Societies; September 5, 2006.
Fleming AD, Philip S, Goatman KA, Olson JA, Sharp PF. Automated microaneurysm detection using local contrast normalization and local vessel detection. IEEE T Med Imaging. 2006 Sep 1;25(9):1223-32. doi: 10.1109/tmi.2006.879953
Schnitzler MA, Earnshaw SR, Graham CN, Irish WD, Sato R. Lifetime cost-effectiveness of calcineruin inhibitor-free immunosuppressive treatment after de novo renal transplantation. Poster presented at the World Transplant Congress; July 27, 2006.
Earnshaw SR, Beard SM, Lynch NO, Cowell W. Ibandronate in the treatment of postmenopausal osteoporosis: a cost-effectiveness analysis in the UK. Poster presented at the European League Against Rheumatism Annual European Congress of Rheumatology; June 24, 2006.
Philip S, Fleming A, Goatman K, Sharp P, Olson J. Automated image quality assessment is an essential step for automating diabetic retinopathy detection. Poster presented at the 66th Scientific Session; June 9, 2006. Washington, DC. [abstract] Diabetes. 2006 Jun 9; 55(supplement 1):A513.
Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, Engelgau MM, Ratner RE, Herman WH. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care. 2006 Jun 1;29(6):1237-41.
Van Houtven CH, Wilson MR, Stearns SC, Clipp E. Depression and missed work among informal caregivers of older individuals with dementia. Poster presented at the AcademyHealth 2006 Annual Research Meeting; June 2006.
Mladsi DM. MMA Part D: how has the US market changed? Presented at the Visiongain 4th Annual Pricing and Reimbursement Conference; May 26, 2006. London, UK.
Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson K. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA.
Candrilli SD, Mauskopf JA. How much does a day in the hospital cost? Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA.
Earnshaw SR, Moride Y, Moshyk A, Rochon S. Cost-effectiveness of macugen compared to photodynamic therapy (PDT) with verteporfin and standard care in the treatment of subfoveal wet age-related macular degeneration (AMD) in the elderly in Canada. Poster presented at the Third Annual Canadian Joint Therapeutics Congress, Canadian Association for Population Therapeutics; May 13, 2006. Toronto, Canada.
Candrilli S, Mackell J. Effect of ncep atp iii guideline revisions on the prevalence of dyslipidemia among the elderly: evidence from nhanes. Poster presented at the 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; May 9, 2006.
Sculpher M, Longson C, Wolowacz SE, Khan S. The new National Institute of Health And Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first round of submissions. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 2006. Philadelphia, PA.
Candrilli S, Mauskopf J. How much does a day in the hospital cost? Value Health. 2006 May 1;9(3):A56.
Moreland S, Talbird SE. Achieving the Millennium Development Goals: the contribution of fulfilling the unmet need for family planning. 2006.
Longson C, Wolowacz SE, Sculpher MJ, Khan SB. The National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: an update on the first round of submission. Presented at the 2006 ISPOR 11th Annual International Meeting; May 2006. Philadelphia, PA.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson KP. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Value Health. 2006 May 1;9(3):A81-2.
McCrink L, Beard SM, Le T. The relationship between health-related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A41.
McCrink L, Beard S, Le TK. The relationship between health related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain (DPNP). Value Health. 2006 May 1;9(3):A41.
Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.
Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.
Earnshaw SR, Graham CN, Amonkar MM, Barr CE. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Value Health. 2006 May 1;9(3):A163.
Mladsi DM, Barrett AM. Winners and losers: patterns in economic evaluations of anti-epileptic drugs. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A83.
Mladsi DM. Developing health economic models for assessing cost-effectiveness and product value. Presented at the 2006 Health Economics Conference; April 28, 2006. London, UK.
Davis KL, Mauskopf J, Chow W, Chao J, Seal B. Titration and persistence with tamsulosin among men with benign prostatic hyperplasia in a large managed care population. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 8, 2006.
Earnshaw SR, Joshi AV, Wilson MR. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US managed care perspective. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 7, 2006.
Earnshaw SR, Gricar J. Good practices for high quality decision analytic models. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 6, 2006.
Javitt JC, Earnshaw SR, Graham CN, Brogan AJ, Zlateva GP, Pleil AM. Cost-effectiveness of Macugen versus no treatment in age-related macular degeneration patients. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting; April 2006.
Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006 Mar 7;144(5):326-36.